ORION CORPORATION INVESTOR NEWS 19 NOVEMBER 2024 at 18.30 EET Orion and Alligator Bioscience amend their agreement concerning two bispecific antibodies Orion Corporation and Alligator Bioscience AB ...

While bispecific antibodies tend to be well-tolerated for patients with multiple myeloma, there are still adverse effects clinicians should discuss with their patients. The use of bispecific ...

Alligator Bioscience AB ("Alligator" or the "Company") announced today that it is sharpening its primary focus on ...

Transaction valued at €3.5 millionThe partners have enjoyed a successful discovery collaboration since 2021LUND, SWEDEN / ACCESSWIRE / November 19, 2024 / Alligator Bioscience (STO:ATORX) today announ ...

The bispecific antibodies market continues to grow due to the use of BsAbs in diagnostics. In general, bsAb is designed to bind a specific antigen and a detection moiety (e.g., horseradish peroxidase) ...

LUND, SWEDEN / ACCESSWIRE / November 19, 2024 / Alligator Bioscience (STO:ATORX) today announced that the Company has entered into an agreement under which Orion Corporation has settled all future ...

The next step for generating bispecific candidate drugs is to combine the isolated binders into a bispecific molecule using a so-called bispecific antibody format, prominent for its geometry and ...

Their support enables us to accelerate the development of our diverse pipeline spanning multiple modalities including next-generation ADCs and bispecific antibodies targeting oncology and ...

MSD has an extensive pipeline in oncology but hasn't been a player in bispecific antibodies. Now, it has bolted on a bispecific via a $1.3 billion licensing deal with Curon Biopharma. The big ...